MediPharm Labs Begins Production of Cannabis Metered Dose Inhalers for European Market Expansion
Key Insights
MediPharm Labs (search) has commenced production of pharmaceutical-grade cannabis metered dose inhalers for distribution in the EU and United Kingdom through exclusive partner Blackpoint Limited (search).
The GMP-manufactured inhalers deliver precise doses of cannabis active pharmaceutical ingredients (search) without combustion, targeting the €834 million European medicinal cannabis market.
The company expects to launch these smoke-free, asthma (search) inhaler-style devices in Australia, EU, and UK markets during Q3 2025.
MediPharm Labs (search) Corp. has initiated production of novel cannabis metered dose inhalers designed for the European Union and United Kingdom markets, marking a significant expansion of the company's pharmaceutical-grade cannabinoid portfolio. The Toronto-based pharmaceutical company announced it has begun manufacturing these innovative delivery devices under Good Manufacturing Practices (GMP) standards for distribution through its exclusive partner Blackpoint Limited (search).
Pharmaceutical-Grade Cannabis Delivery Innovation
The metered dose inhaler represents a breakthrough in medical cannabis delivery, providing patients with a smoke-free, vapor-free alternative that delivers precise doses of cannabis active pharmaceutical ingredients (search) (API). Unlike traditional consumption methods, the device eliminates combustion and heating while ensuring consistent and repeatable dosing similar to conventional asthma (search) inhalers.
"We're excited to expand our international portfolio and partner with Blackpoint to bring our innovative cannabis metered dose inhaler (search) to the EU and United Kingdom," said David Pidduck, CEO of MediPharm Labs (search). "This smoke- and vapor-free format supports our mission to advance global access to pharma-grade cannabinoid wellness products."
The inhaler utilizes GMP-qualified components and excipients, manufactured under stringent pharmaceutical standards to ensure the highest quality and safety for medical applications. This approach addresses patient concerns regarding stigma, odor, and byproducts associated with traditional smoking or vaping methods.
Strategic Market Entry and Distribution
MediPharm Labs (search) has secured exclusive supply and manufacturing rights for Blackpoint Limited (search), which will handle distribution across EU and UK territories. The partnership includes minimum purchase obligations designed to ensure steady product availability in designated markets.
David Martinez, CEO of Blackpoint, emphasized the collaboration's potential impact: "Working together with the highly capable team at MediPharm is exciting and we look forward to introducing our novel and much needed metered dose products for the benefit of the growing number of patients across the EU and United Kingdom."
The European medicinal cannabis market represents substantial commercial opportunity, with Prohibition Partners estimating the market value at €834 million in 2024. This expansion builds upon MediPharm's existing presence in Canadian adult-use, wellness, and medical channels, where the company has already launched similar metered dose inhaler products.
Regulatory Positioning and Manufacturing Capabilities
MediPharm Labs (search) holds a unique regulatory position in the cannabis pharmaceutical space. In 2021, the company received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold commercial-scale domestic GMP licensing for multiple natural cannabinoid extraction. This certification served as the foundation for the company's current foreign drug manufacturing site registration with the US FDA (search).
The company's manufacturing infrastructure includes ISO standard-built clean rooms and state-of-the-art purification methodologies designed specifically for pharmaceutical-quality cannabis concentrates and API production. These capabilities enable international product launches while maintaining compliance with varying regulatory requirements across different jurisdictions.
Global Expansion Timeline
MediPharm Labs (search) expects to launch the metered dose inhalers in Australia, the EU, and the United Kingdom during the third quarter of 2025. This timeline reflects the company's systematic approach to international market entry, managing complexities related to compliance, logistics, and market access across multiple regulatory environments.
The expansion strategy leverages the company's 2023 acquisition of VIVO Cannabis Inc. (search), which extended MediPharm's reach to medical patients through established platforms including Canna Farms in Canada, Beacon Medical PTY (search) in Australia, and Beacon Medical GMBH (search) in Germany. The acquisition also included Harvest Medical Clinics (search), providing integrated patient consultation services for medical cannabis education and prescriptions.
Clinical Applications and Patient Benefits
The metered dose inhaler format offers several clinical advantages for medical cannabis patients. The device provides rapid onset of effects without the respiratory irritation associated with combustion methods, while delivering consistent dosing that enables better treatment outcomes and symptom management.
The familiar inhaler format reduces barriers to patient adoption, particularly among populations already comfortable with similar devices for conditions such as asthma (search) or chronic obstructive pulmonary disease (search). This design consideration addresses both medical efficacy and patient acceptance factors that influence treatment compliance.
MediPharm's focus on precision-based cannabinoids aligns with growing demand for standardized medical cannabis products that meet pharmaceutical quality standards. The company's research-driven approach and purpose-built facilities support the development of advanced cannabinoid-based products for both domestic and international medical markets.